Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.

Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. Biogen (NASDAQ: BIIB) reported ...

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Denali Therapeutics (DNLI – Research Report) today and set a price target of $28.00. The company’s shares opened today at $30.23.

Pitcairn Co. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 3rd quarter, ...

Denali Therapeutics Inc. (Nasdaq: NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ...

Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Denali Therapeutics (NASDAQ:DNLI) on Friday, setting a price target of $111, which is approximately 101.74% above ...